Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease.
about
The generation and function of soluble apoE receptors in the CNSAlzheimer mechanisms and therapeutic strategiesImpact of apolipoprotein E on Alzheimer's diseaseApolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapyCerebrospinal Fluid Particles in Alzheimer Disease and Parkinson DiseaseGenetic variants associated with neurodegenerative Alzheimer disease in natural modelsInflammation and Alzheimer's diseaseStructural basis for the recognition and cross-linking of amyloid fibrils by human apolipoprotein EReelin and apoE actions on signal transduction, synaptic function and memory formationApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosisIn vivo human apolipoprotein E isoform fractional turnover rates in the CNSSelection of peptides binding to the amyloid b-protein reveals potential inhibitors of amyloid formation.Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors.Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ε4 allele.Use of genetic variation as biomarkers for Alzheimer's disease.Increased expression of cholesterol transporter ABCA1 is highly correlated with severity of dementia in AD hippocampus.APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesisGenetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathologyThe effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease.Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway.Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrierSoluble amyloid-β levels and late-life depressionPlasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry.Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model.Apolipoprotein E gene promoter polymorphisms in Alzheimer's disease.Apolipoprotein E isoforms in Alzheimer's disease pathology and etiology.Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid-beta deposition in vivo.Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein.Use of genetic variation as biomarkers for mild cognitive impairment and progression of mild cognitive impairment to dementia.Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses.Genetic connections between neurological disorders and cholesterol metabolismAnimal models of amyloid-beta-related pathologies in Alzheimer's disease.The complex interaction between APOE promoter and AD: an Italian case-control studyBinding of apolipoprotein E inhibits the oligomer growth of amyloid-β peptide in solution as determined by fluorescence cross-correlation spectroscopy.Apolipoprotein E: from lipid transport to neurobiologyRole of apoE/Abeta interactions in Alzheimer's disease: insights from transgenic mouse models.The role of apolipoprotein E in Alzheimer's disease.Effects of human apolipoprotein E isoforms on the amyloid beta-protein concentration and lipid composition in brain low-density membrane domainsLipoprotein lipase is a novel amyloid beta (Abeta)-binding protein that promotes glycosaminoglycan-dependent cellular uptake of Abeta in astrocytes.Apolipoproteins in the brain: implications for neurological and psychiatric disorders.
P2860
Q21202840-B7ACC040-AA1F-4B4B-8E3F-3AC92091B0EEQ22252311-D4A324FE-835C-4F4C-809D-8E2B580452FDQ24567759-636C14C0-6A4C-4436-B91F-15E5B9B9B718Q24604376-C648D93E-93AE-4854-80C4-CB5419B7BCE2Q27314618-EA746B51-CF3F-4FF0-804E-CAC148914CFFQ28079843-736991AB-9AFA-4226-B6AF-368E1609015CQ28138617-1B0A6DC5-C9E5-48DD-A927-E3AB556D4A09Q28252183-3A30BB38-513B-44E6-8973-8BC35A6B6789Q28254650-A3A485CD-A299-4861-A1E0-C4BD737224DBQ28504715-0894AC51-EF6E-4AD9-A3D3-3A0F8BF4DD00Q28728902-99739AA8-493E-4044-8ABC-2017F0CCC118Q30805913-F3E3A15B-408C-4BD7-9577-09C5CE8607EFQ30855109-8A9AF74F-F1B4-481B-875E-C1669D8675C1Q33363912-5A1FD133-5FEE-420D-80B9-047E606BF90EQ33640956-057671DC-6801-4F7C-901C-8F2EC2291B83Q33679171-09CF4D22-2318-422A-BD95-62852B94213DQ33759956-7468DD99-927A-4857-8E38-38CAF84D9119Q33811028-A4DF87DD-AE63-460E-9AD3-5B81D94FD586Q33841363-65E02FBC-19F7-4B2A-9D31-4F0A5664C655Q33924453-D6D4EAD5-9056-433D-9D08-8FAA031004BFQ33928434-D1BDCCBD-E65A-44EE-8D4F-0AC156DBAA4BQ33933220-412F43CB-5162-4847-8C3E-1239409147F3Q33947437-553BC59D-AAA0-42BB-A294-E4FC0E299218Q33960315-5F7FFC14-74F9-47CE-A70D-5B8AFA5430BFQ33998647-0814028B-37AC-4D28-996D-7EDB69A9621CQ33998664-C05D9E02-C932-43B9-8840-34374F528D32Q33998681-B708B654-C58C-4FA1-8387-8602903C6ED1Q33998693-34CFA7E9-6F96-4B31-89CA-273990F05011Q34013606-299A8D0C-E8D6-412B-9D54-EB5CFF69DFB1Q34045304-B84EA245-EB50-4CCB-B03F-6994ECCF652AQ34053056-A5CC3BBF-CCC4-41E1-8726-6EBEF0E4DBC1Q34097190-10BB0D11-C85C-4BBB-8A23-B119E1447D76Q34326720-3FDF5C94-3CBD-4F17-9FCA-30B0B815A5C9Q34329102-784C05A3-C122-4314-BFE4-C897FE893E44Q34497951-6DEFF908-7F7A-4A1A-B9CE-D82EBFE58DF5Q34526548-E7152668-4094-4263-AE50-0AB2BF01DBAFQ34603092-68E74F53-187A-405F-B0F5-0DE2C43B4BE7Q34624644-E9A895C4-9A46-4040-8D1B-097FFB201B87Q34675772-C967DDDF-1C47-49C0-B14B-0E61E99D281CQ34680878-B639F95A-A0F1-47BF-9736-776BF5A2C5FE
P2860
Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Expression of human apolipopro ...... model of Alzheimer's disease.
@en
type
label
Expression of human apolipopro ...... model of Alzheimer's disease.
@en
prefLabel
Expression of human apolipopro ...... model of Alzheimer's disease.
@en
P2093
P2860
P356
P1476
Expression of human apolipopro ...... model of Alzheimer's disease.
@en
P2093
D M Holtzman
M Parsadanian
P2860
P304
P356
10.1172/JCI6179
P407
P577
1999-03-01T00:00:00Z